Extended use of dabigatran no better than warfarin for high-risk patients after VTE

There was no benefit to dabigatran (Pradaxa) over warfarin in patients felt to be at high risk for recurrent venous thromboembolism (VTE): there were a similar number of deaths and a similar number of the combination of critical bleeds and recurrent episodes of VTE.

Extended use of dabigatran no better than warfarin for high risk patients after VTE

Add yours ↓
Web design and marketing agency Leamington Spa